The EMBRACA trial (NCT01945775) found that single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival among patients with advanced BC and a germline BRCA1/2 mutation [40] and could be used as a potential BC treatment in those patients. The gene discussed is BRCA1; the disease is breast cancer.